Skip to content
Download PDF

Lysosomal Storage Diseases

Chapter 429 | Harrison's 22e · Part 12 – Endocrinology & Metabolism · Chapter 429

Key Clinical Points

  1. Over 50 different lysosomal storage diseases (LSDs) exist, categorized by the nature of the major accumulated materials: proteins, nucleic acids, carbohydrates, and lipids.
  2. Lysosomes are heterogeneous organelles requiring an acidic environment for the dissociation of receptors/ligands and the activation of hydrolases.
  3. Lysosomal function is part of the lysosome/autophagy/mitophagy system, regulated by mTORC1 via phosphorylation of transcription factors TFEB/TFE3 to balance anabolic and catabolic pathways.
  4. LSDs can result from defects at any biosynthetic step, including leader sequence clipping, mannose-6-phosphate tagging, or post-translational modifications (phosphorylation, sulfation, proteolytic processing, macromolecular assembly).
  5. Inheritance patterns vary: most are autosomal recessive; others include X-linked (Hunter and Fabry) and autosomal dominant (Danon and two conditions causing Parry type neuronal ceroid lipofuscinosis due to DNAJC5 or progranulin mutations).
  6. Clinical presentation varies from severe to attenuated phenotypes, with common features including neurologic/renal/muscular degeneration, hepatomegaly, splenomegaly, cardiomyopathy, and skeletal dysplasias.
  7. Diagnosis is established through clinical presentation, enzyme assays (to identify specific hydrolase deficiencies), or genetic testing for definitive diagnosis.

DEFINITION & CLASSIFICATION

• Definition: Lysosomes are heterogeneous subcellular organelles containing specific hydrolases that allow selective processing or degradation of proteins, nucleic acids, carbohydrates, and lipids.

• Classification: Currently termed lysosomal system diseases (LSDs). Categorized by the nature of the major accumulated materials: 1. Proteins 2. Nucleic acids 3. Carbohydrates 4. Lipids

• Scope: >50 different LSDs identified.

PATHOGENESIS

• Lysosomal Biogenesis: Involves synthesis of: 1. Lysosomal hydrolases 2. Membrane constitutive proteins 3. New membranes

• Formation & Activation: Lysosomes originate from the fusion of trans-Golgi network vesicles and late endosomes. Progressive acidification is required for: 1. pH-dependent dissociation of receptors and ligands 2. Activation of lysosomal hydrolases

• Regulation: Part of the lysosome/autophagy/mitophagy system. Regulated by mTORC1 modulation via phosphorylation of transcription factors TFEB/TFE3. Function: Controls the balance between anabolic and catabolic pathways.

• Pathogenic Mechanisms: Abnormalities at any biosynthetic step can impair lysosomal enzyme function and lead to an LSD. Critical steps include: 1. Leader sequence clipping from the protein 2. Remodeling of complex oligosaccharides (including mannose-6-phosphate) 3. High-mannose oligosaccharide chains 4. Sorting of membrane proteins via several peptide signals 5. Post-translational modifications (phosphorylation, sulfation, proteolytic processing, macromolecular assembly)

• Final Common Pathway: Accumulation of specific macromolecules in tissues/cells with high flux of these substrates → lysosomal dysfunction → significant pathophysiology.

GENETICS

• Inheritance Patterns: Most LSDs are inherited as autosomal recessive disorders. Exceptions include: 1. X-linked: Hunter (mucopolysaccharidosis type II) and Fabry disease. 2. Autosomal dominant: Danon, and two conditions causing Parry type neuronal ceroid lipofuscinosis (CLN) due to DNAJC5 or progranulin mutations.

CLINICAL FEATURES

• Presentation Spectrum: Clinical manifestations vary from severe to attenuated phenotypes.

• Common Clinical Findings: Specific to the disease, but often included in the differential diagnosis of patients with: 1. Neurologic, renal, or muscular degeneration 2. Unexplained hepatomegaly 3. Splenomegaly 4. Cardiomyopathy 5. Skeletal dysplasias and deformations

DIFFERENTIAL DIAGNOSIS

• Key Disorders to Consider: 1. Tay-Sachs disease 2. Fabry disease 3. Gaucher disease 4. Niemann-Pick disease (Types A, B, and C) 5. Mucopolysaccharidoses 6. Pompe disease 7. Lysosomal acid lipase deficiency (LALD) 8. Krabbe disease 9. CLN2-related Batten disease 10. α-mannosidosis

DIAGNOSTIC APPROACH

  1. Clinical Presentation: Identification of specific symptoms (e.g., hepatomegaly, splenomegaly, cardiomyopathy) → suspicion of LSD.
  2. Enzyme Assays: Used to identify specific hydrolase deficiencies.
  3. Genetic Testing: Used to provide a definitive diagnosis and identify specific variants.

MANAGEMENT & TREATMENT

  1. General Management: Treatment of hepatic complications, which may be accompanied by motor neuropathy, is difficult.

  2. Pharmacological Interventions: a. Cholestyramine and other nucleic acid porphyrin absorbents (e.g., activated charcoal) → may interrupt the enterohepatic circulation of protoporphyrin → promote its fecal excretion → some improvement. b. Plasmapheresis and intravenous hemin → sometimes beneficial.

  3. Transplantation Options: a. Liver transplantation → performed in some cases with severe liver complications; often successful in the short term, but disease often recurs in the transplanted liver due to bone marrow production of excess protoporphyrin. b. Bone marrow transplantation → should be considered after liver transplantation if a suitable donor is available (successfully prevented liver disease in mouse models).

KEY PEARLS & HIGH-YIELD POINTS

• Diversity: Over 50 types of LSDs exist, categorized by the type of accumulated material. • Mechanism: Any defect in lysosomal biogenesis (enzyme synthesis, membrane protein formation, or mannose-6-phosphate tagging) can result in an LSD. • Genetics: Most are autosomal recessive; Hunter and Fabry are X-linked; Danon and CLN are autosomal dominant. • Diagnosis: Definitive diagnosis is achieved via enzyme assays or genetic testing.